| Mekinist (trametinib) / Novartis, BeiGene |
NCT01978236: Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites |
|
|
| Terminated | 2b | 6 | US, RoW | Dabrafenib 150 mg, Trametinib 2.0 mg | GlaxoSmithKline | Melanoma and Brain Metastases | 04/17 | 04/17 | | |
NCT01037127: Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor |
|
|
| Completed | 2 | 97 | US | GSK1120212 | GlaxoSmithKline | Cancer | 07/11 | 01/13 | | |
|
|
|
NCT01328106: Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma |
|
|
| Withdrawn | 2 | 0 | NA | GSK1120212 | GlaxoSmithKline | GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma | 08/11 | 05/12 | | |
NCT01928940: Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) |
|
|
| Completed | 2 | 12 | Japan | dabrafenib, trametinib | GlaxoSmithKline | Solid Tumours | 09/14 | 07/16 | | |
NCT01701037: Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery |
|
|
| Terminated | 2 | 13 | US | dabrafenib, BRAF inhibitor GSK2118436, GSK2118436, trametinib, GSK1120212, laboratory biomarker analysis | Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), National Comprehensive Cancer Network | Recurrent Melanoma, Stage IIB Melanoma (Locally Advanced), Stage IIC Melanoma (Locally Advanced), Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma (Limited, Resectable) | 02/15 | 04/15 | | |
NCT01619774: An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor |
|
|
| Completed | 2 | 28 | US | GSK2118436, GSK1120212 | M.D. Anderson Cancer Center, Cancer Prevention Research Institute of Texas, GlaxoSmithKline | Melanoma | 08/15 | 08/15 | | |
|
NCT01721603: Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets |
|
|
| Terminated | 2 | 2 | US | Dabrafenib, GSK2118436, Gamma Knife Radiosurgery, SRS, Stereotactic Radiosurgery, Trametinib, GSK1120212 | University of California, San Francisco, GlaxoSmithKline | BRAFV600E Melanoma Patients | 01/16 | 01/16 | | |
NCT02314143: Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib |
|
|
| Terminated | 2 | 48 | Europe | Dabrafenib, Trametinib | GlaxoSmithKline | Melanoma | 01/17 | 01/17 | | |
NCT02296996: Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients |
|
|
| Completed | 2 | 25 | Europe | Dabrafenib + Trametinib | Universitair Ziekenhuis Brussel | Malignant Melanoma | 12/17 | 12/17 | | |
NCT02087254: Study for the Evaluation Dabrafenib (Tafinlar) and Trametinib (Mekinist) Plus DNE3 in Patients With Metastatic Melanoma |
|
|
| Terminated | 1/2 | 78 | RoW | Dabrafenib, Tafinalar, GSK2118436, Trametinib, Mekinist, GSK1120212, DNE3, Dioscorea nipponica Makino with ethyl acetate (DNE3) | Cancer Centre of Monoclonal Therapy, LLC, National Cancer Institute (NCI), Melanoma Research Foundation | Melanoma, Metastatic Melanoma | 12/14 | 05/17 | | |
